Brenus has closed an €11 million ($12.6 million) extension to its Series A funding round, pushing the Lyon, France-based biotech's total capital raised to €38 million ($43.5 million) since inception. The extension signals growing international investor confidence in the company's lead clinical-stage asset and immunotherapy platform. The funding will support the continued development of STC-1010 (NCT06934538), the company's lead clinical-stage in vivo immunotherapy targeting microsatellite stable metastatic colorectal cancer (MSS mCRC). According to the company, the investment reflects successful de-risking of STC-1010 while positioning Brenus's platform for multi-asset expansion beyond its initial program. The funding round marks a significant milestone in Brenus’s geographic diversification.